CoChat
Cited by 163

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis

Open access
Tanaka, Kosuke, Yu, Helena A., Yang, Shaoyuan, Han, Song, Selcuklu, S. Duygu, Kim, Kwanghee, Ramani, Shriram, Ganesan, Yogesh Tengarai, Moyer, Allison, Sinha, Sonali, Xie, Yuchen, Ishizawa, Kota, Osmanbeyoglu, Hatice U., Lyu, Yang, Roper, Nitin, Guha, Udayan, Rudin, Charles M., Kris, Mark G., Hsieh, James J., Cheng, Emily H. · 2021 · Cancer Cell

Abstract

SUMMARY The clinical success of EGFR inhibitors in EGFR-mutant lung cancer is limited by the eventual development of acquired resistance. We hypothesize that enhancing apoptosis through combination therapies can eradicate cancer cells and reduce the emergence of drug tolerant persisters. Through high-throughput screening of a custom library of ~1,000 compounds, we discover Aurora B kinase inhibitors as potent enhancers of osimertinib-induced apoptosis. Mechanistically, Aurora B inhibition stabilizes BIM through reduced Ser87 phosphorylation, and transactivates PUMA through FOXO1/3. Importantly, osimertinib-resistance caused by epithelial–mesenchymal transition (EMT) activates the ATR-CHK1-Aurora B signaling cascade and thereby engenders hypersensitivity to respective kinase inhibitors by activating BIM-mediated mitotic catastrophe. Combined inhibition of EGFR and Aurora B not only efficiently eliminates cancer cells but also overcomes resistance beyond EMT.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2021.07.006

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 163

Metadata

Authors
Tanaka, K., Yu, H. A., Yang, S., Han, S., Selcuklu, S. D., Kim, K., Ramani, S., Ganesan, Y. T., Moyer, A., Sinha, S., Xie, Y., Ishizawa, K., Osmanbeyoglu, H. U., Lyu, Y., Roper, N., Guha, U., Rudin, C. M., Kris, M. G., Hsieh, J. J., & Cheng, E. H.
Venue
Cancer Cell
Publisher
Elsevier BV
Published
2021-09
Volume
39
Issue
9
Pages
1245-1261.e6
ISSN
1535-6108 (ISSN-L)
OpenAlex
W3190172544
Cited by
163
References
28
FWCI
14.18
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. https://app.cochat.ai/papers/10.1016/j.ccell.2021.07.006
The paper
Tanaka, K., Yu, H. A., Yang, S., Han, S., Selcuklu, S. D., Kim, K., Ramani, S., Ganesan, Y. T., Moyer, A., Sinha, S., Xie, Y., Ishizawa, K., Osmanbeyoglu, H. U., Lyu, Y., Roper, N., Guha, U., Rudin, C. M., Kris, M. G., Hsieh, J. J., & Cheng, E. H. (2021). Targeting Aurora B kinase prevents and overcomes resistance to EGFR inhibitors in lung cancer by enhancing BIM- and PUMA-mediated apoptosis. Cancer Cell. https://doi.org/10.1016/j.ccell.2021.07.006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.